Aligos Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $135,704 | $81,347 |
| Restricted cash | 70 | 115 |
| Short-term investments | - | 44,480 |
| Other current assets | 5,310 | 7,603 |
| Total current assets | 141,084 | 133,545 |
| Operating lease right-of-use assets | 6,559 | 7,698 |
| Property and equipment, net | 3,259 | 4,816 |
| Other assets | 625 | 634 |
| Total assets | $151,527 | $146,693 |
| LIABILITIES AND | ||
| STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,517 | $4,737 |
| Accrued liabilities | 16,842 | 16,039 |
| Operating lease liabilities, current | 3,229 | 3,035 |
| Finance lease liabilities, current | 10 | 108 |
| Deferred revenue from customers, current | 1,224 | 467 |
| Deferred revenue from collaborations, current | 84 | 8,743 |
| Total current liabilities | 23,906 | 33,129 |
| Operating lease liabilities, net of current portion | 7,668 | 9,201 |
| Finance lease liabilities, net of current portion | 231 | 230 |
| Deferred revenue from customers, net of current portion | - | 233 |
| Warrant liability | 27,596 | - |
| Long term liability | 46 | - |
| Total liabilities | 59,447 | 42,793 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | - | - |
| Common stock, $0.0001 par value; 320,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 75,096,906 and 42,922,980 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 7 | 4 |
| Additional paid-in capital | 578,325 | 502,613 |
| Accumulated deficit | (486,797) | (399,118) |
| Accumulated other comprehensive income | 545 | 401 |
| Total stockholders’ equity | 92,080 | 103,900 |
| Total liabilities and stockholders’ equity | $151,527 | $146,693 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.